H-Cys(Bzl)-OH
Names
[ CAS No. ]:
3054-01-1
[ Name ]:
H-Cys(Bzl)-OH
[Synonym ]:
Alanine, 3- (benzylthio)-, L-
D-S-Benzylcysteine
EINECS 221-273-4
MFCD00002613
H-CYS(BZL)-OH
H-L-CYS(BZL)-OH
S-Benzyl-L-Cysteine
Benzylcysteine
(L)-2-amino-3-(benzylthio)propanoic acid
(S)-BENZYL-L-CYS
(S)-S-benzylcysteine
L-Cysteine, S- (phenylmethyl)-
L-S-benzylcysteine
(R)-2-Amino-3- (S-Benzylthio)Propanoic Acid
S-Benzylcysteine
BENZYL-S-CYSTEINE
(R)-2-Amino-3-(benzylthio)propanoic acid
Cysteine, S-(phenylmethyl)-
S-Bzl-L-Cys
CYSTEINE(BZL)-OH
Biological Activity
[Description]:
[Related Catalog]:
[In Vitro]
[References]
Chemical & Physical Properties
[ Density]:
1.3±0.1 g/cm3
[ Boiling Point ]:
379.2±42.0 °C at 760 mmHg
[ Melting Point ]:
209-214ºC
[ Molecular Formula ]:
C10H13NO2S
[ Molecular Weight ]:
211.281
[ Flash Point ]:
183.2±27.9 °C
[ Exact Mass ]:
211.066696
[ PSA ]:
88.62000
[ LogP ]:
2.10
[ Vapour Pressure ]:
0.0±0.9 mmHg at 25°C
[ Index of Refraction ]:
1.609
MSDS
Safety Information
[ Personal Protective Equipment ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
[ Hazard Codes ]:
Xn
[ Safety Phrases ]:
S24/25
[ RIDADR ]:
NONH for all modes of transport
[ WGK Germany ]:
3
[ HS Code ]:
2930909090
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Customs
[ HS Code ]: 2930909090
[ Summary ]:
2930909090. other organo-sulphur compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%
Articles
Rapid Commun. Mass Spectrom. 29(1) , 119-27, (2014)
Data analysis is a key step in mass spectrometry based untargeted metabolomics, starting with the generation of generic peak lists from raw liquid chromatography/mass spectrometry (LC/MS) data. Due to...
Formation of a dehydroalanyl residue from S-benzylcysteine upon HF cleavage of a [Sar1, Cys8]-angiotensin II peptide resin.Int. J. Pept. Protein Res. 38(6) , 601-2, (1991)
Synthesis and biological evaluation of L-cysteine derivatives as mitotic kinesin Eg5 inhibitors.
Bioorg. Med. Chem. Lett. 17 , 3921-4, (2007)
Inhibition of Eg5 represents a novel approach for the treatment of cancer. Here, we report the synthesis and structure-activity relationship of S-trityl-L-cysteine (STLC) derivatives as Eg5 inhibitors...